MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025. Recent Financial Highlights: Total revenue of $83.5 million in the third quarter of 2025, compared to $38.4 million in the third quarter of 2024, an increase of ...

MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for third quarter ended September 30, 2025 after the market close on Tuesday, December 9, 2025. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. To partic ...

Core Points - BillionToOne, Inc. successfully closed its upsized initial public offering (IPO) of 5,233,765 shares of Class A common stock at a public offering price of $60.00 per share, resulting in gross proceeds of approximately $314.0 million before deductions [1] - The IPO included the full exercise of the underwriters' option to purchase an additional 682,665 shares [1] - The company's Class A common stock began trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025 [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4] Offering Details - The registration statement related to the securities was filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025 [2] - A prospectus describing the terms of the offering has been filed with the SEC and is available on their website [2]

Core Points - BillionToOne, Inc. has announced the pricing of its upsized initial public offering (IPO) of 4,551,100 shares at a price of $60.00 per share, with gross proceeds expected to be approximately $273.1 million [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025, and is expected to close on November 7, 2025, subject to customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 682,665 shares at the initial public offering price [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [5] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [5] Underwriters - The joint book-running managers for the offering include J.P. Morgan, Piper Sandler, Jefferies, and William Blair, with Stifel, Wells Fargo Securities, and BTIG also acting as book-running managers [2]

Core Viewpoint - BillionToOne, Inc. has launched a roadshow for its proposed initial public offering (IPO) of 3,846,000 shares of Class A common stock, with an expected price range of $49.00 to $55.00 per share [1]. Company Overview - BillionToOne is a molecular diagnostics company based in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4]. - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4]. IPO Details - The proposed IPO includes a 30-day option for underwriters to purchase an additional 576,900 shares at the initial offering price, excluding underwriting discounts and commissions [1]. - The company has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "BLLN" [1]. - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the offering, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [1].